Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
POLARITYTE INC (PTE) Stock Price & Overview
NASDAQ:PTE • US7310942070
Current stock price
0.241 USD
0 (-0.82%)
At close:
0.2249 USD
-0.02 (-6.68%)
After Hours:
The current stock price of PTE is 0.241 USD. Today PTE is down by -0.82%. In the past month the price decreased by -36.91%. In the past year, price decreased by -85.39%.
PTE Key Statistics
52-Week Range0.2 - 1.9
Current PTE stock price positioned within its 52-week range.
1-Month Range0.2 - 0.44
Current PTE stock price positioned within its 1-month range.
- Market Cap
- 1.778M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.41
- Dividend Yield
- N/A
PTE Stock Performance
Today
-0.82%
1 Week
-3.60%
1 Month
-36.91%
3 Months
-65.05%
Longer-term
6 Months -65.41%
1 Year -85.39%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
PTE Stock Chart
PTE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PTE. When comparing the yearly performance of all stocks, PTE is a bad performer in the overall market: 98.58% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
PTE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PTE. Both the profitability and financial health of PTE have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PTE Earnings
Next Earnings DateAug 9, 2023
Last Earnings DateMay 12, 2023
PeriodQ1 / 2023
EPS Reported-$0.58
Revenue Reported
EPS Surprise 16.77%
Revenue Surprise %
PTE Forecast & Estimates
5 analysts have analysed PTE and the average price target is 0.82 USD. This implies a price increase of 238.59% is expected in the next year compared to the current price of 0.241.
For the next year, analysts expect an EPS growth of 48.01% and a revenue growth -100% for PTE
Analysts
Analysts80
Price Target0.82 (240.25%)
EPS Next Y48.01%
Revenue Next Year-100%
PTE Financial Highlights
Over the last trailing twelve months PTE reported a non-GAAP Earnings per Share(EPS) of -2.41. The EPS increased by 61.44% compared to the year before.
Income Statements
Revenue(TTM)73.00K
Net Income(TTM)-8.30M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%74.22%
Sales Q2Q%-100%
EPS 1Y (TTM)61.44%
Revenue 1Y (TTM)-98.66%
PTE Ownership
Ownership
Inst Owners0%
Shares7.38M
Float7.13M
Ins Owners114.99%
Short Float %N/A
Short RatioN/A
PTE Industry Overview
PTE operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
PTE Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PTE
Company Profile
PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The company is headquartered in Salt Lake City, Utah and currently employs 42 full-time employees. Its first regenerative tissue product is SkinTE. Its SkinTE is intended for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm's development projects include SkinTE Point-of-Care Device, SkinTE Cryo and Other Tissue Regeneration Products. SkinTE Cryo allows it to offer multiple deployments from one original harvest through a cryopreservation process. The core technology of SkinTE is minimally polarized functional units (MPFUs). MPFUs are multi-cellular segments created from a piece of the patient’s healthy skin.
Company Info
IPO: 1999-08-13
POLARITYTE INC
1960 S. 4250 West
Salt Lake City UTAH 84116 US
CEO: David Seaburg
Employees: 42
Phone: 13852663151.0
POLARITYTE INC / PTE FAQ
What does PTE do?
PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The company is headquartered in Salt Lake City, Utah and currently employs 42 full-time employees. Its first regenerative tissue product is SkinTE. Its SkinTE is intended for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm's development projects include SkinTE Point-of-Care Device, SkinTE Cryo and Other Tissue Regeneration Products. SkinTE Cryo allows it to offer multiple deployments from one original harvest through a cryopreservation process. The core technology of SkinTE is minimally polarized functional units (MPFUs). MPFUs are multi-cellular segments created from a piece of the patient’s healthy skin.
Can you provide the latest stock price for POLARITYTE INC?
The current stock price of PTE is 0.241 USD. The price decreased by -0.82% in the last trading session.
What is the dividend status of POLARITYTE INC?
PTE does not pay a dividend.
What is the ChartMill technical and fundamental rating of PTE stock?
PTE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for PTE stock?
POLARITYTE INC (PTE) currently has 42 employees.